About alumis inc - ALMS
Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.
ALMS At a Glance
Alumis, Inc.
280 East Grand Avenue
San Francisco, California 94080
| Phone | 1-650-231-6625 | Revenue | 24.05M | |
| Industry | Pharmaceuticals: Major | Net Income | -243,325,000.00 | |
| Sector | Health Technology | Employees | 224 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ALMS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 34.507 |
| Price to Book Ratio | 3.392 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.317 |
| Enterprise Value to Sales | 23.211 |
| Total Debt to Enterprise Value | 0.066 |
ALMS Efficiency
| Revenue/Employee | 107,366.071 |
| Income Per Employee | -1,086,272.321 |
| Receivables Turnover | 11.546 |
| Total Asset Turnover | 0.064 |
ALMS Liquidity
| Current Ratio | 4.34 |
| Quick Ratio | 4.34 |
| Cash Ratio | 4.209 |
ALMS Profitability
| Gross Margin | 85.464 |
| Operating Margin | -1,776.316 |
| Pretax Margin | -1,047.343 |
| Net Margin | -1,011.746 |
| Return on Assets | -64.276 |
| Return on Equity | -86.685 |
| Return on Total Capital | -71.945 |
| Return on Invested Capital | -78.138 |
ALMS Capital Structure
| Total Debt to Total Equity | 12.252 |
| Total Debt to Total Capital | 10.914 |
| Total Debt to Total Assets | 8.871 |
| Long-Term Debt to Equity | 10.702 |
| Long-Term Debt to Total Capital | 9.534 |